• Explore /
  • Poster
  • / Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

Abstract Poster

Authors

Ivan Marquez-Rodas

Ivan Marquez-Rodas

Medical Oncology, General University Hospital Gregorio Marañón & CIBERONC, Madrid, Spain

Ivan Marquez-Rodas , Stéphane Dalle , Eduardo Castanon , Miguel F. Sanmamed , Ana Maria Arance , Pablo Cerezuela-Fuentes , Roberto Martin Huertas , Juan Francisco Rodríguez-Moreno , Maria Gonzalez-Cao , Eva Muñoz-Couselo , Juan Martin-Liberal , Delvys Rodriguez-Abreu , Ángel Alberich-Bayarri , Irene Mayorga-Ruiz , Miguel Angel Molina Vila , Ruth Román , Marya F. Chaney , Javier Sánchez López , Sonia Maciá , Marisol Quintero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04570332

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS9586)

DOI

10.1200/JCO.2021.39.15_suppl.TPS9586

Abstract #

TPS9586

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hazel Lote

First Author: Nicholas Coupe

First Author: Brian Gastman

First Author: Tony S. K. Mok